ES2946697T3 - Una población celular para su uso en el tratamiento de cáncer - Google Patents

Una población celular para su uso en el tratamiento de cáncer Download PDF

Info

Publication number
ES2946697T3
ES2946697T3 ES15770464T ES15770464T ES2946697T3 ES 2946697 T3 ES2946697 T3 ES 2946697T3 ES 15770464 T ES15770464 T ES 15770464T ES 15770464 T ES15770464 T ES 15770464T ES 2946697 T3 ES2946697 T3 ES 2946697T3
Authority
ES
Spain
Prior art keywords
cells
bdca1
cd1c
cell
bdca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15770464T
Other languages
English (en)
Spanish (es)
Inventor
Vries Jolanda De
Carl Figdor
Ghaith Bakdash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Miltenyi Biotec GmbH
Original Assignee
Miltenyi Biotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miltenyi Biotec GmbH filed Critical Miltenyi Biotec GmbH
Application granted granted Critical
Publication of ES2946697T3 publication Critical patent/ES2946697T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES15770464T 2014-09-10 2015-09-10 Una población celular para su uso en el tratamiento de cáncer Active ES2946697T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14184334 2014-09-10
EP14184333 2014-09-10
EP14184687 2014-09-12
PCT/EP2015/070778 WO2016038168A1 (en) 2014-09-10 2015-09-10 A cell population for use in treting cancer

Publications (1)

Publication Number Publication Date
ES2946697T3 true ES2946697T3 (es) 2023-07-24

Family

ID=54196941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15770464T Active ES2946697T3 (es) 2014-09-10 2015-09-10 Una población celular para su uso en el tratamiento de cáncer

Country Status (5)

Country Link
US (2) US10925944B2 (cg-RX-API-DMAC7.html)
EP (1) EP3191109B1 (cg-RX-API-DMAC7.html)
JP (1) JP6712262B2 (cg-RX-API-DMAC7.html)
ES (1) ES2946697T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016038168A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136633A1 (en) * 2016-02-04 2017-08-10 Duke University Cell-based vaccine compositions and methods of use
US11083751B2 (en) 2016-02-26 2021-08-10 Vib Vzw Tumor-associated dendritic cell preparations and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2021006316A1 (ja) * 2019-07-10 2021-01-14 国立研究開発法人国立がん研究センター がん細胞を特異的に攻撃しているt細胞を同定するための特異的マーカー
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN120177299B (zh) * 2024-12-03 2026-06-12 江苏省人民医院(南京医科大学第一附属医院) 利用流式细胞仪识别慢性粒单核细胞免疫分型的抗体组合物及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
AU7499498A (en) * 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
CA2385792A1 (en) 1999-10-08 2001-04-19 Dendreon Corporation Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells
JP5007007B2 (ja) 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
US7030228B1 (en) * 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU3279301A (en) * 2000-01-11 2001-07-24 Maxygen, Inc. Monocyte-derived dendritic cell subsets
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
US10925944B2 (en) 2021-02-23
EP3191109A1 (en) 2017-07-19
US11612644B2 (en) 2023-03-28
WO2016038168A1 (en) 2016-03-17
JP6712262B2 (ja) 2020-06-17
JP2017528470A (ja) 2017-09-28
EP3191109B1 (en) 2023-03-29
US20170258882A1 (en) 2017-09-14
US20210038702A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
US11612644B2 (en) Cell population for use in treating cancer
Martins et al. Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker
Lecciso et al. ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells
ES2776926T3 (es) Composición medicinal para tratamiento del cáncer
Bugaut et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells
JP7515209B2 (ja) 癌免疫療法用mr1制限t細胞受容体
JP2021521776A (ja) Mage−b2特異性を有するt細胞受容体およびその使用
KR20230016183A (ko) 키메라 항원 수용체를 발현하는 바이러스 특이적 면역 세포
CN107847585B (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
BR112013024395B1 (pt) Composições adotivas de imunoterapia celular e método para fabricação da dita composição
CA2937499A1 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
CN111182917A (zh) 用于治疗癌症的免疫原性组合物
Cho et al. Engineered CD8+ T cell-derived extracellular vesicles induce enhanced anti-cancer efficacy and targeting to lung cancer cells
US20190389926A1 (en) Mr1 restricted t cell receptors for cancer immunotherapy
Jähn et al. BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation
WO2021062313A1 (en) Immunogenic egfr peptide compositions and their use in the treatment of cancer
JP2022543026A (ja) Nk細胞を評価するためのシステム及び方法
WO2017040374A1 (en) Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
ES2955819T3 (es) Linfocitos T modificados para inmunoterapia adoptiva
US20250367289A1 (en) Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
WO2019043065A1 (en) METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS
Donini Preclinical exploration of a novel cellular immunotherapy with CAR-redirected cytokine-induced killer lymphocytes (CIK) against soft tissue sarcomas
Shute Glycolipid-Loaded Nanoparticles Harness Invariant Natural Killer T Cells for Tumor Immunotherapy
Rumolo Isolation, expansion and characterization of tumor infiltrating lymphocytes derived from metastatic colorectal carcinoma patients for adoptive immunotherapy
AU2024330614A1 (en) Chimeric antigen receptor constructs and uses thereof